CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR and Bayer, would operate under the direct management of CRISPR. Upon closing of the transaction, Casebia would focus on the development of its lead programs in hemophilia, ophthalmology and autoimmune diseases, with Bayer having opt-in rights for two products at […]

The FDA has approved Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have the most common CF-causing mutation. With this approval, for the first time, approximately 6,000 people with CF ages 12 years and older who have one F508del mutation and one minimal function mutation […]

Boston-based Alexion Pharmaceuticals is set to acquire Achillion, a clinical-stage biopharma focused on the development of oral small molecule Factor D inhibitors to treat complement alternative pathway-mediated rare diseases. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, […]

Cambridge-based Ra Pharmaceuticals is being acquired by UCB, a global biopharma focused on diseases of the immune system or the central nervous system. Under the terms of the agreement, Ra Pharma shareholders will receive $48 in cash for each Ra Pharma share at closing. The Boards of Directors of both companies have unanimously approved the […]

Flagship Pioneering has unveiled Cambridge-based Cygnal Therapeutics which was founded in 2017 in Flagship Labs. Cygnal is the first company to develop drugs in the field of exoneural biology, a new understanding of how nerves and neural signaling drive human health and disease. The company has discovered biologically relevant pathways and advanced starting points for […]